Table 1 Comparison of demographic and clinical characteristics between survivors and non-survivors
Survivors, n = 462 | Non-survivors, n = 48 | P value | |
|---|---|---|---|
Age, months | 1.37 [0.33–16.0] | 0.97 [0.33–13.5] | 0.540 |
Age group, n | |||
≤ 28 days, n = 239 | 215 (46.5) | 24 (50.0) | 0.893 |
≤ 1 year, n = 132 | 120 (26.0) | 12 (25.0) | |
> 1 year, n = 139 | 127 (27.5) | 12 (25.0) | |
Body weight, kg | 4.2 [2.5–11.0] | 2.9 [1.5–10.0] | 0.035 |
Male, n | 277 (60.0) | 27 (56.3) | 0.645 |
Illness severitya, score | 6 [3–9] | 10 [6–14] | <0.001 |
Diagnosis on ICU admission | |||
Respiratory diseases, n | 176 (38.1) | 10 (20.8) | 0.054 |
Neurologic diseases, n | 59 (12.8) | 1 (2.1) | |
Preterm/LBW, n | 37 (8.0) | 5 (10.4) | |
Sepsis, n | 45 (9.7) | 11 (22.9) | |
Poison/trauma/accident, n | 34 (7.4) | 5 (10.4) | |
Cardiologic diseases, n | 20 (4.3) | 1 (2.1) | |
Gastroenterologic, n | 19 (4.1) | 0 (0) | |
Hematologic diseases, n | 17 (3.7) | 6 (12.5) | |
MVb, n | 127 (27.5) | 35 (72.9) | <0.001 |
MV duration, days | 0 [0–0.84] | 2.23 [0–6.86] | <0.001 |
MV duration ≥ 48 hours, n | 89 (19.3) | 24 (50.0) | <0.001 |
AKIc, n | 63 (13.6) | 16 (33.3) | 0.002 |
AKI stage 1, n | 36 (7.8) | 7 (14.6) | <0.001 |
AKI stage 2, n | 19 (4.1) | 5 (10.4) | |
AKI stage 3, n | 8 (1.7) | 4 (8.3) | |
Sepsisb, n | 58 (9.7) | 15 (22.9) | 0.001 |
Shock/DICb, n | 61 (13.2) | 13 (27.1) | 0.013 |
MODSb, n | 65 (14.1) | 14 (29.2) | 0.009 |
Furosemideb, n | 126 (27.3) | 24 (50.0) | 0.002 |
Steroidb, n | 150 (32.5) | 21 (43.8) | 0.147 |
Antibioticsb, n | 418 (90.5) | 46 (95.8) | 0.294 |
Vancomycinb, n | 35 (7.6) | 7 (14.6) | 0.099 |
Mannitolb, n | 115 (24.9) | 16 (33.3) | 0.225 |
Inotropeb, n | 60 (13.0) | 10 (20.8) | 0.182 |
Hemofiltrationb, n | 15 (3.2) | 3 (6.3) | 0.235 |
Initial uCysC, ng/mg uCr | 311.82 [122.22–975.34] | 1587.39 [583.19–8749.16] | <0.001 |
Peak uCysC, ng/mg uCr | 426.49 [165.23–1607.62] | 7026.73 [1285.25–33879.56] | <0.001 |